Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Item

http://www.wikidata.org/entity/Q34611341

Q34611341

about

Effectiveness of Ivabradine in Treating Stable Angina Pectoris Ivabradine, coronary artery disease, and heart failure: beyond rhythm control Heart rate and use of beta-blockers in stable outpatients with coronary artery disease Heart Rate Reduction With Ivabradine Protects Against Left Ventricular Remodeling by Attenuating Infarct Expansion and Preserving Remote-Zone Contractile Function and Synchrony in a Mouse Model of Reperfused Myocardial Infarction Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats.Ivabradine for the treatment of stable angina pectoris in octogenarians.Risk-benefit assessment of ivabradine in the treatment of chronic heart failure ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β-Blocker Therapy.Ivabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathy A Review of the Key Clinical Trials of 2014.Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate.Biological Heart Rate Reduction Through Genetic Suppression of Gα(s) Protein in the Sinoatrial Node.Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options.Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand?Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice.The Role of Ivabradine in the Management of Angina Pectoris.Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena?Antianginal Efficacy of Ivabradine in Patients With History of Coronary Revascularization.The Impact of Different Plasma Glucose Levels on Heart Rate in Experimental Rats With Acute Myocardial Infarction Rate control with ivabradine: angina pectoris and beyond.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Ivabradine: recent and potential applications in clinical practice.Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.Cardioprotection by ivabradine through heart rate reduction and beyond.Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.Stable angina pectoris: antianginal therapies and future directions.Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice.Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.Heart rate reduction in heart failure: ivabradine or beta blockers?Medical management of stable coronary atherosclerosis.'Inappropriate' sinus tachycardia: does the 100 beats per min cut-off matter?Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.Treatment of refractory angina in patients not suitable for revascularization.An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.Heart failure: novel therapeutic approaches.A focus on the prognosis and management of ischemic heart disease in patients without evidence of obstructive coronary artery disease.Heart rate and its reduction in chronic heart failure and beyond.Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.

P2860

Q26750710-30B042DC-5B88-4DB2-B13E-D03AC4776C28 Q26865770-91CD7122-BC22-4223-AFE9-41E44FB59C3C Q28730142-334FCA57-3D47-4037-B086-27E06B53B8CC Q30276924-9A334CF3-177D-4CB9-AB38-83FA2A67E8A9 Q30318221-5837E7E8-ED48-4F62-BE38-6982241F1895 Q30431487-3E330CAB-5043-40B5-92F9-DD8C14AAAB08 Q33159163-DC78749E-7C66-42BC-B8EA-10A70AEE7F40 Q33568592-7010D607-3CF8-4784-A210-13C6B543CCFE Q33647497-591881E4-D7F2-4392-8183-0BD44C4B2110 Q33717188-18B8CAB3-EAEF-4D20-BDDF-28036F7BCB69 Q34387839-F1DB2F30-7360-4911-8500-AD49874DE14C Q35756614-7E720257-DE9E-4B7E-A488-D95D1ED26BA8 Q36059223-11D22CDC-E184-4BBD-A6D7-CF2870B42554 Q36366373-FB9240AB-7791-4D35-8A9E-EE18CDBEA687 Q37140881-65CD86B6-D703-42F6-8979-0C0475756882 Q37233293-0F97FBB8-4B5C-46D6-9FF5-199A8EE1BBE6 Q37250491-D423A4C8-4138-4EE1-9A07-4D041CD22948 Q37298004-3B72D883-ED7E-4A08-AB3C-027A2D6AC19A Q37398110-7336A511-681E-4EB4-857F-972575EC032B Q37495266-FCEEF2DC-053C-47D2-BA77-0B11650076BF Q37629279-A02CCE07-9EF7-4422-ACEB-82D752533B16 Q37810893-1579D575-5A17-47E3-BEB6-DD868801CC66 Q37827882-6826BA28-3122-434F-98DC-4278FCD02CCD Q37831353-6F3C6702-D5E8-427A-A010-A852EF20C5C7 Q37857335-59B751BD-2BCC-465A-B8F6-6B08370BFA4D Q37912844-31D6F562-F93F-4850-AC23-6B7981DF539B Q37923966-D1A38435-15EB-445A-8294-DBD939E3F81F Q37924086-E3723F03-6AA9-413F-B897-8E3AF8CC3C19 Q37964807-67DCB32B-5769-4250-8E78-9B5A9BBA100C Q37986643-B76C77F4-A28F-4AC9-B3DD-17E639AAD2E5 Q38042855-28D5FBC6-4398-421D-A0EF-B1C18DC21B6E Q38083007-BFBD7122-AB62-4AB5-8769-8DE021AAF727 Q38086846-0DAE03A0-C65E-4931-A3CA-FA8189AE383A Q38142792-73A9129E-9C10-4D27-8FDF-BBAD107F68A9 Q38173640-65DD70A3-2F11-4A58-96A4-CDD419C42DF1 Q38174653-6EFD1AA2-7E20-4418-88FC-B007B547E5F0 Q38376055-6AA02B47-B7E4-4A6D-9BEA-84F8E7E90E5F Q38574181-14460413-8FE1-4D44-8567-DA1E7B196ECA Q38669556-4A683FCB-EDD4-46C7-ACA9-BDC27FF92AD1 Q38797276-4D0731DB-B00E-46A2-854E-BC1E7A0D56ED

P2860

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Item

http://www.wikidata.org/entity/Q34611341

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue